Details werden geladen...
EAN 2026
12. Congress of the European Academy of Neurology - EAN 2026
Veranstaltungen
27.06.2026 00:00 - 30.06.2026 00:00
12. Congress of the European Academy of Neurology
12. Congress of the European Academy of Neurology
Genève
Ähnliche Seiten
Johnson & Johnson: New IMAAVY Data Reinforces Sustained Disease Control In GMG | 26.06.26 | finanzen.at
https://www.finanzen.at/nachrichten/aktien/johnson-&-johnson-new-imaavy-data-reinforces-sustained-disease-control-in-gmg-1036280004
Johnson & Johnson: New IMAAVY Data Reinforces Sustained Disease Control In GMG | 26.06.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/johnson-&-johnson-new-imaavy-data-reinforces-sustained-disease-control-in-gmg-1036280004
Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis | The Manila T...
https://www.manilatimes.net/2026/06/27/tmt-newswire/globenewswire/johnson-johnson-presents-new-imaavy-nipocalimab-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalised-myasthenia-gravis/2373918EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss | The Manila Times
https://www.manilatimes.net/2026/06/27/tmt-newswire/pr-newswire/ean-congress-hearing-aid-use-linked-to-23-lower-dementia-risk-in-people-with-both-epilepsy-and-hearing-loss/2374012Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease | The Manila Times
https://www.manilatimes.net/2026/06/27/tmt-newswire/globenewswire/monopar-presents-new-analyses-of-phase-3-focus-data-at-ean-2026-showing-greater-neurologic-and-global-clinical-benefit-with-alxn1840-versus-standard-of-care-in-wilson-disease/2373970